engleski

PHARMACOPHORE-BASED HYBRIDS OF NUCLEOSIDES AND 1, 2, 3-TRIAZOLES

Nucleoside analogs have acquired an important role as therapeutic agents in the field of chemotherapy on account of their extensive biological activities. Introduction of a triazole ring into nucleosides to improve their bioactivity for antitumor or antiviral applications has become wide spread in drug design practices.1, 2 The 1, 2, 3-triazole unit may be considered as a surrogate of the amide group because these moieties have a similar H-bond acceptor capacity, a similar distance between substituents, and a similar dipolar properties. Keeping into consideration the biological potency of 1, 2, 3- triazolo-nucleosides and in our continuous endeavor toward the synthesis of pharmacologically active molecules, we designed and synthesized 1, 2, 3-triazole embedded N-heterocycles (Figure 1.) in order to evaluate their cytostatic activities. The concept of molecular hybridization has been adopted for the design and synthesis of diversified library of pseudopurine isostere and 1, 2, 3-triazole conjugates. Some representatives of pseudopurine-1, 2, 3-triazole hybrids have shown selective inhibitory activity against evaluated malignant tumor cell lines (lung carcinoma (A-549) and hepatocellular carcinoma (Hep G-2)). The target regioselective 1, 4-disubstituted 1, 2, 3- triazole derivatives were prepared by the Cucatalyzed alkyne-azide cycloaddition (CuAAC) using modern and eco-friendly synthetic approaches such as microwave and ultrasound assisted reaction.

hybrids, nucleosides, 1, 2, 3-triazole

nije evidentirano